{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.4","upperLimit":"11.4","value":"7.9"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"28.6","value":"9.3"},{"groupId":"OG002","lowerLimit":"5.6","upperLimit":"10.7","value":"7.4"},{"groupId":"OG003","lowerLimit":"7.0","upperLimit":"28.5","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"39"}],"units":"Participants"}],"description":"PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.","id":"OG000","title":"Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.","id":"OG001","title":"Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.","id":"OG002","title":"Part D: Dabrafenib 75 mg + Trametinib 2 mg"},{"description":"Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.","id":"OG003","title":"Part D: Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the earliest date of disease progression (PD) or death due to any cause (up to approximately 7 years)","title":"Part D: Progression-free Survival (PFS) as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Months"}